Samsung Biologics Steps into 'BIX2024'... "Establishing First Solo Booth"

Samsung Biologics announced on the 9th that it will participate in 'BioPlus-Interphex Korea 2024 (BIX 2024),' the largest comprehensive bio and pharmaceutical convention in Korea.

BIX2024 Samsung Biologics Promotional Booth Bird's-eye View
[Photo by Samsung Biologics]

Hosted by the Korea Bio Association and Reed Exhibitions (RX) Korea, BioPlus-Interphex Korea 2024 is a platform for sharing the value chain of the domestic and international bio and pharmaceutical industries and discussing partnerships through business networking.

Under the theme of "The World's Best Practical Bio and Healthcare Convention," this year's BIX 2024 will be held for three days from the 10th to the 12th at COEX in Gangnam-gu, Seoul, with an expected attendance of 250 companies and over 10,000 participants.

Samsung Biologics will set up a standalone booth within the exhibition hall at this year's BIX 2024. This is the first time Samsung Biologics is creating a standalone booth at BIX. At this event, the company plans to actively promote its continuously expanding Contract Manufacturing Organization (CMO) capabilities and newly developed Contract Development Organization (CDO) technology platforms, showcasing its enhanced global Contract Development and Manufacturing Organization (CDMO) capabilities.

The booth will feature LED screens and wall graphics introducing the world's largest production capacity of 1,324,000 liters, which is planned to be secured by constructing plants 5 to 8 at the second bio campus by 2032. It will also highlight the differentiated competitiveness of CDO services and an expanded portfolio including antibodies, Antibody-Drug Conjugates (ADC), and messenger RNA (mRNA). In particular, with the completion and operation of a dedicated production facility for ADC drugs, recognized as next-generation anticancer agents, scheduled within the year, Samsung Biologics will actively enter the ADC CDMO competition to secure clients.

Additionally, at the conference session organized as a side event, Heonchang Lim, Head of the Formulation Development Group, will participate as a speaker to introduce Samsung Biologics' new drug candidate discovery platform DevelopPick and CDO capabilities under the theme "DevelopPick 3.0: Successful Candidate Selection and New Drug Development Using Development Feasibility Assessment Tools."

Moreover, to minimize traditional brochure printing for booth visitors, Samsung Biologics plans to provide digital brochures via QR codes, eco-friendly souvenirs, and jute bags, demonstrating its commitment to ESG (Environmental, Social, and Governance) practices.

During the event, Samsung Biologics will also conduct online and offline sponsorship activities to enhance brand awareness. The company plans to install banners at the exhibition booth and display digital banners on its website and newsletters to increase recognition of Samsung Biologics' vision and service competitiveness.